All In Biotech

NDA 203684 · Bracco

Lumason

Sulfur Hexafluoride Lipid-Type A Microspheres · Intravenous · Contrast Agent for Ultrasound Imaging

Novel

Last checked: Nov 20, 2026Latest source record: Apr 9, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Oct 10, 2014

Approved uses

4

Original approval plus efficacy supplements

Registered trials

27

7 Phase 3, 7 recruiting

FAERS reports

1,980

1,360 serious, 101 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions ( 5.1 )] . Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions ( 5.1 )] . Assess all patients for the presence of any condition that precludes administration [see Contraindications ( 4 )] . Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions ( 5.1 )] . WARNING: SERIOUS CARDIOPULMONARY REACTIONS See full prescribing information for complete boxed warning Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride...

What it is approved for

From the label in effect Sep 9, 2026.

Echocardiography Lumason is indicated for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. Ultrasonography of the Liver Lumason is indicated for use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions. Ultrasonography of the Urinary Tract Lumason is indicated for use in ultrasonography of the urinary tract in pediatric patients for the evaluation of suspected or known vesicoureteral reflux. Lumason is an ultrasound contrast agent indicated for use in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult and pediatric patients with suboptimal echocardiograms ( 1 ) in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients ( 1 ) in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients ( 1 )

Mechanism: Within the blood, the acoustic impedance of Lumason microspheres is lower than that of the surrounding non-aqueous tissue. Therefore, an ultrasound beam is reflected from the interface between the microspheres and the surrounding tissue. The reflected ultrasound signal provides a visual image that shows a contrast between the blood and the surrounding tissues. For ultrasonography of the urinary tract in pediatric patients, the intravesically administered Lumason microspheres increase signal intensity of fluids within the urethra, bladder, ureters, and renal pelvis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LUMASON · SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES 60.7MG/25MG · FOR SUSPENSION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sulfur Hexafluoride Lipid A Microspheres" as an intervention, any sponsor and status, largest first.

All 27 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea335
  • nausea277
  • anaphylactic reaction252
  • hyperhidrosis231
  • flushing196
  • hypotension168
  • dizziness162
  • feeling hot157
  • hypersensitivity136
  • erythema135
  • blood pressure decreased125
  • unresponsive to stimuli123

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201217
20139
20141
20151
201622
201734
201860
201969
202072
2021129
2022215
2023448
2024280
2025277
2026346

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Lumason (Sulfur Hexafluoride Microsphr) · HCPCS Q9950

2024 spending

$314K

Beneficiaries

3,798

4,038 claims

Per beneficiary

$83

2024 ASP limit $18.88 per unit

View as table
YearSpending
2020$511,720
2021$243,089
2022$323,440
2023$323,788
2024$313,880

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3 on PubMed

Sponsor: Bracco

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.